COPD

Introduction Chronic obstructive pulmonary disease is the most common respiratory disease in Germany. People with COPD suffer from chronic obstructive pulmonary disease (COPD). This term describes a group of lung diseases that are all associated with an increasing narrowing of the small airways. COPD is favoured by inhaled noxious agents, such as cigarette smoking. Symptoms … COPD

Causes of COPD | COPD

Causes of COPD The term COPD is mainly used to describe chronic inflammation of the airways (chronic bronchitis) and the restructuring of the lung architecture (pulmonary emphysema). Many factors contribute to its development. The most frequent cause of chronic inflammation and narrowing of the airways is a long-lasting inflammation and increased production of mucus in … Causes of COPD | COPD

Frequency of COPD | COPD

Frequency of COPD Chronic bronchitis is the most common chronic lung disease. Approximately 20% of all men suffer from it. Women are significantly less affected. For every woman who is ill, there are 3 – 4 ill men. It is estimated that about 44 million people are affected worldwide. In Germany about 15% of the … Frequency of COPD | COPD

Vilanterol

Products Vilanterol is commercially available as a fixed combination with fluticasone furoate in powder inhaler form (Relvar Ellipta / Breo Ellipta). It was approved in the US and EU in 2013 and in many countries in 2014. The fixed combination with umeclidinium bromide (Anoro Ellipta) was also registered in many countries in 2014. In 2017, … Vilanterol

Salmeterol

Products Salmeterol is commercially available as metered-dose inhalers and discs (Serevent, Seretide + fluticasone). It has been approved in many countries since 1995. Structure and properties Salmeterol (C25H37NO4, Mr = 415.6) is present in the drugs as a racemate and as salmeterol xinafoate, a white powder that is sparingly soluble in water. It is structurally … Salmeterol

Indacaterol

Products Indacaterol is commercially available as hard capsules with a powder for inhalation (Onbrez Breezhaler) and has been approved since 2010. It is also combined fixed with the LAMA glycopyrronium bromide (Ultibro Breezhaler, approved 2014). The fixed combination with mometasone furoate (Atectura Breezhaler) was registered for asthma therapy in 2020. Finally, a combination of indacaterol … Indacaterol